Navigation Links
ValGenesis, Inc., the Leading Provider of Validation Lifecycle Management Solutions to Regulated Life Science Companies, Today Announced Support for EMC Documentum v.6.5
Date:9/3/2009

gurable workflow provided by ValGenesis. ValGenesis offers Documentum users strengthened return on investment and additional usability, functionality and productivity," said Siva Samy, Ph.D., ValGenesis Chief Product Strategist.

About ValGenesis

ValGenesis offers an innovative software platform that serves as the foundation for compliance-based validation life cycle management in regulated companies by enabling a 100% paperless validation process. ValGenesis is the first Enterprise application to automate the validation lifecycle and to provide 360-degree visibility to the corporate validation process. ValGenesis is designed to fully conform to FDA 21 CFR Part 11 compliance requirements. Through an industry peer review committee, the Parenteral Drug Association (PDA) awarded ValGenesis the prestigious New Innovative Technology award.

    For more information, contact:

    Mike Beaudro, 510-445-0505, mike.beaudro@valgenesis.com
    Website:http://www.valgenesis.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE ValGenesis, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ValGenesis, Inc. Announces Integration of ValGenesis Solution with Microsoft SharePoint Server
2. ValGenesis, Inc. Announces Worldwide Release of Validation Life Cycle Management System - ValGenesis 2.0
3. BioStorage Technologies, Inc., Welcomes Catherine Michael as Global Head of Sample Management Operations
4. Sigma-Aldrich Acquires ChemNavigator, Inc., to Provide Researchers With Industry-Leading Chemical Compound Selection and Procurement Services
5. avVaa World Health Care Products, Inc. Signs Agreement with 3PL Worldwide, Inc., for Order Management & Fulfillment for avVaas Product
6. BioStorage Technologies, Inc., Appoints Jeff Goddard to Global Head of Sales
7. Buehler Motor, Inc., Significantly Expands Customer and Partner Support in North America
8. Providence-Based NABsys, Inc., Announces $4 Million Equity Financing
9. CRO Acquisition Seen Boosting Activity, Positioning ASG, Inc., for New Growth in Q2
10. iZumi Bio, Inc., Appoints John Walker as Chief Executive Officer
11. Helsinn Announces the Acquisition of Sapphire Therapeutics Inc., USA to Establish Helsinn Therapeutics (US) Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/15/2010)... YORK , March 15 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc.,(NYSE Amex: NBS ... and China , announced,today a change for the Company,s presentation at the ... 15, 2010 .,NeoStem,s presentation will now take place at 10:30 a.m. Pacific ... ... ...
(Date:3/15/2010)... YORK , March 15 /PRNewswire-Asia-FirstCall/ -- American Oriental,Bioengineering, Inc. (NYSE: ... improving health through the development, manufacture and,commercialization of a broad range of ... fourth quarter and fiscal,year ended December 31, 2009 . ,, ... ... ...
(Date:3/14/2010)... , March 14 /PRNewswire/ -- Results from a landmark study involving more than 9,000 people showed that the high blood ... condition. , ... , , ... ... ...
(Date:3/12/2010)... Vermillion, Inc. (Pink Sheets: VRML) today announced that Medicare will ... mass is benign or malignant. Highmark Medicare Services is the CMS contractor ... to cover this new service. , ... ... ...
Breaking Biology Technology:NeoStem Announces Presentation Time Change at Roth Capital Partners 22nd Annual OC Growth Stock Conference 2NeoStem Announces Presentation Time Change at Roth Capital Partners 22nd Annual OC Growth Stock Conference 3American Oriental Bioengineering Reports Fourth Quarter and Full Year 2009 Financial Results 2American Oriental Bioengineering Reports Fourth Quarter and Full Year 2009 Financial Results 3American Oriental Bioengineering Reports Fourth Quarter and Full Year 2009 Financial Results 4American Oriental Bioengineering Reports Fourth Quarter and Full Year 2009 Financial Results 5American Oriental Bioengineering Reports Fourth Quarter and Full Year 2009 Financial Results 6American Oriental Bioengineering Reports Fourth Quarter and Full Year 2009 Financial Results 7American Oriental Bioengineering Reports Fourth Quarter and Full Year 2009 Financial Results 8American Oriental Bioengineering Reports Fourth Quarter and Full Year 2009 Financial Results 9American Oriental Bioengineering Reports Fourth Quarter and Full Year 2009 Financial Results 10American Oriental Bioengineering Reports Fourth Quarter and Full Year 2009 Financial Results 11American Oriental Bioengineering Reports Fourth Quarter and Full Year 2009 Financial Results 12NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 2NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 3NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 4NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 5NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 6NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 7NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 8NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 9NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 10NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 11NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 12NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 13Medicare Establishes Reimbursement Coverage for Vermillion's OVA1(TM) Test 2Medicare Establishes Reimbursement Coverage for Vermillion's OVA1(TM) Test 3Medicare Establishes Reimbursement Coverage for Vermillion's OVA1(TM) Test 4
... MannKind Corporation (Nasdaq: MNKD ), focused on ... announced today that it will present at the 11th ... on Monday, February 9, 2009 at 2:15 PM (EST) ... In addition to this presentation, the Company ...
... genetic materialSAN DIEGO, Feb. 2 Following three years ... veterans today announced the formation of SG Biofuels ... in the development of Jatropha as a low-cost, sustainably ... Chief Executive Officer, introduced the company at the 2009 ...
... To highlight its 20 years of experience as ... ( www.microtestlabs.com ) is offering free microbial identification ... tests, to eligible attendees visiting the Microtest exhibit, #828, ... highlight Microtest,s wide range of laboratory testing and validation ...
Other Biology Technology:MannKind to Present at the 11th Annual Biotechnology Industry Organization BIO CEO & Investor Conference 2Energy, Biotechnology and Agribusiness Veterans Form SG Biofuels to Develop Jatropha as Low-Cost, Sustainable Oil 2Microtest Labs Offers Free Microbial Identification Testing, Free Shipping on Other Tests, to MD&M West Attendees 2
(Date:3/15/2010)... Plasmodium vivax ( P. vivax ) malaria ... be resistant to the disease, those who do not ... blood cells, according to researchers from Case Western Reserve ... Ministry of Health. In a study of more than ... transmission areas of Madagascar, the researchers found that 10 ...
(Date:3/15/2010)... with a cup of steaming hot coffee. Although ... brew," coffee contains several nutrients (eg, calcium) as ... (eg, polyphenols) that may promote health. For instance, ... coffee consumption and type 2 diabetes. Determining whether ... controlled intervention trials. Two articles published in the ...
(Date:3/15/2010)... This release is available in Spanish . ... a healthy weight before they become pregnant, and to ... pregnancy. Now ongoing studies by Agricultural Research Service (ARS)-funded ... insights into those recommendations. , Shankar is ... occur in the womband perhaps during the first few ...
Breaking Biology News(10 mins):Duffy-negative blood types no longer protected from P. Vivax malaria 2Duffy-negative blood types no longer protected from P. Vivax malaria 3Baby's obesity risk: What's the mother's influence? 2Bird flu leaves the nest adapting to a new host 9699 1Hill Rom to Participate at the Thomas Weisel Partners 2009 Healthcare Conference 55399 1Hill Rom to Participate at the Thomas Weisel Partners 2009 Healthcare Conference 55399 2Versa Card Inc Opens First Treatment Center for Spine Pain Management Inc 55395 1Versa Card Inc Opens First Treatment Center for Spine Pain Management Inc 55395 2
... has successfully protected mice and ferrets against a highly ... led the study at St. Jude Children's Research Hospital. ... Diego, California. , This finding, coupled with results of ... strains, suggests that such a vaccine would protect humans ...
... To study the bacteria which survive in extreme cold, ... such as Antarctic lakes and glaciers. Bacteria previously isolated ... to survive in extreme cold, have been isolated from ... her colleagues at Queen's University, Canada, have developed a ...
... that generate the strongest immune response in mice, ... a vaccine that significantly protects immunized animals from ... most common cause of hospital-acquired infections and a ... The vaccine protected mice against potentially lethal infections ...
Other Biology News:St. Jude test of bird flu vaccine proves successful 2MRSA vaccine shows promise in mouse study 2MRSA vaccine shows promise in mouse study 3
... Re-Blot Western Blot Recycling Kit is ... Western blots that have been developed ... other isotopes. It is not recommended ... 4-chloronapthol, etc.), as it is not ...
... Immulon ... surface to provide increased binding affinity ... Flat bottom works well for ... optical characteristics., Each ...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
... relax positively and negatively supercoiled DNA in presence ... Studying the effects of supercoiling on transcription in ... , Determining the degree of supercoiling of ... that differ in length by only one base-pair ...
Biology Products: